These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 14592467)

  • 1. Hydrolysis of 4-HPR to atRA occurs in vivo but is not required for retinamide-induced apoptosis.
    Chapman JS; Weiss KL; Curley RW; Highland MA; Clagett-Dame M
    Arch Biochem Biophys; 2003 Nov; 419(2):234-43. PubMed ID: 14592467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapeutic evaluation of 4-hydroxybenzylretinone (4-HBR), a nonhydrolyzable C-linked analog of N-(4-hydroxyphenyl) retinamide (4-HPR) against mammary carcinogenesis.
    Abou-Issa H; Curley RW; Alshafie GA; Weiss KL; Clagett-Dame M; Chapman JS; Mershon SM
    Anticancer Res; 2001; 21(6A):3839-44. PubMed ID: 11911255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The unhydrolyzable fenretinide analogue 4-hydroxybenzylretinone induces the proapoptotic genes GADD153 (CHOP) and Bcl-2-binding component 3 (PUMA) and apoptosis that is caspase- dependent and independent of the retinoic acid receptor.
    Anding AL; Chapman JS; Barnett DW; Curley RW; Clagett-Dame M
    Cancer Res; 2007 Jul; 67(13):6270-7. PubMed ID: 17616685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Hydroxybenzyl modification of the highly teratogenic retinoid, 4-[(1E)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-propen-1-yl]benzoic acid (TTNPB), yields a compound that induces apoptosis in breast cancer cells and shows reduced teratogenicity.
    Anding AL; Nieves NJ; Abzianidze VV; Collins MD; Curley RW; Clagett-Dame M
    Chem Res Toxicol; 2011 Nov; 24(11):1853-61. PubMed ID: 21939267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-HPR Is an Endoplasmic Reticulum Stress Aggravator and Sensitizes Breast Cancer Cells Resistant to TRAIL/Apo2L.
    Anding AL; Jones JD; Newton MA; Curley RW; Clagett-Dame M
    Anticancer Res; 2018 Aug; 38(8):4403-4416. PubMed ID: 30061204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
    Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
    Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.
    Xu H; Cheepala S; McCauley E; Coombes K; Xiao L; Fischer SM; Clifford JL
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):969-79. PubMed ID: 16467112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl)retinamide] sufficient for cancer therapy?
    Ohlmann CH; Jung C; Jaques G
    Int J Cancer; 2002 Aug; 100(5):520-6. PubMed ID: 12124800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinational treatment with retinoic acid derivatives in non-small cell lung carcinoma in vitro.
    Choi EJ; Whang YM; Kim SJ; Kim HJ; Kim YH
    J Korean Med Sci; 2007 Sep; 22 Suppl(Suppl):S52-60. PubMed ID: 17923756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular glutathione levels determine cell sensitivity to apoptosis induced by the antineoplasic agent N-(4-hydroxyphenyl) retinamide.
    Morales MC; Pérez-Yarza G; Nieto-Rementeria N; Boyano MD; Jangi M; Atencia R; Asumendi A
    Anticancer Res; 2005; 25(3B):1945-51. PubMed ID: 16158929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells.
    Ozpolat B; Tari AM; Mehta K; Lopez-Berestein G
    Leuk Lymphoma; 2004 May; 45(5):979-85. PubMed ID: 15291358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production.
    Simeone AM; Broemeling LD; Rosenblum J; Tari AM
    Oncogene; 2003 Oct; 22(43):6739-47. PubMed ID: 14555987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the effect of ATRA, 4-HPR, and CD437 in bladder cancer cells.
    Zou C; Zhou J; Qian L; Feugang JM; Liu J; Wang X; Wu S; Ding H; Zou C; Liebert M; Grossman HB
    Front Biosci; 2006 Sep; 11():2007-16. PubMed ID: 16720286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma.
    Sheikh MS; Shao ZM; Li XS; Ordonez JV; Conley BA; Wu S; Dawson MI; Han QX; Chao WR; Quick T
    Carcinogenesis; 1995 Oct; 16(10):2477-86. PubMed ID: 7586155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent cytotoxic effects of novel retinamide derivatives in ovarian cancer cells.
    Um SJ; Sin HS; Han HS; Kwon YJ; Kim EJ; Park SH; Kim SY; Bae TS; Park JS; Rho YS
    Biol Pharm Bull; 2003 Oct; 26(10):1412-7. PubMed ID: 14519946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biotransformation and biological activity of N-(4-hydroxyphenyl)retinamide derivatives in rodents.
    Swanson BN; Newton DL; Roller PP; Sporn MB
    J Pharmacol Exp Ther; 1981 Dec; 219(3):632-7. PubMed ID: 6170750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).
    Faderl S; Lotan R; Kantarjian HM; Harris D; Van Q; Estrov Z
    Leuk Res; 2003 Mar; 27(3):259-66. PubMed ID: 12537979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.
    Weiss KL; Alshafie G; Chapman JS; Mershon SM; Abou-Issa H; Clagett-Dame M; Curley RW
    Bioorg Med Chem Lett; 2001 Jun; 11(12):1583-6. PubMed ID: 11412986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of rat mammary cancer development by N-(4-hydroxyphenyl)retinamide (4-HPR) following surgical removal of first palpable tumor.
    Moon RC; Pritchard JF; Mehta RG; Nomides CT; Thomas CF; Dinger NM
    Carcinogenesis; 1989 Sep; 10(9):1645-9. PubMed ID: 2527636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth suppression of human breast carcinoma cells in culture by N-(4-hydroxyphenyl)retinamide and its glucuronide and through synergism with glucarate.
    Bhatnagar R; Abou-Issa H; Curley RW; Koolemans-Beynen A; Moeschberger ML; Webb TE
    Biochem Pharmacol; 1991 May; 41(10):1471-7. PubMed ID: 1826840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.